Anzeige
Mehr »
Dienstag, 14.07.2026 - Börsentäglich über 12.000 News
Gold-Kupfer-Knaller 2026?: 483 Gramm Gold pro Tonne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A426PN | ISIN: US22978P2056 | Ticker-Symbol: 1UC0
Tradegate
13.07.26 | 13:34
32,500 Euro
+0,87 % +0,280
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CUE BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
CUE BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
27,12027,28013.07.
0,0000,00013.07.

Aktuelle News zur CUE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
MoCue Biopharma names Dominic Borie as CMO and head of R&D3
MoCue Biopharma Appoints Dominic Borie As CMO4
MoCue Biopharma names Dominic Borie as chief medical officer4
CUE BIOPHARMA Aktie jetzt für 0€ handeln
MoCue Biopharma ernennt Dominic Borie zum neuen Chief Medical Officer4
MoCue Biopharma, Inc.: Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development150BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced...
► Artikel lesen
FrCue Biopharma, Inc. - 8-K, Current Report1
FrCue Biopharma to raise $50M in oversubscribed private placement1
FrCue Biopharma raises $50M in private placement2
FrCue Biopharma, Inc.: Cue Biopharma Announces $50.0 Million Private Placement3
03.06.Cue Biopharma, Inc. - 8-K, Current Report7
03.06.Cue Biopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
02.06.Cue Biopharma, Inc.: Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution190Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance...
► Artikel lesen
14.05.Cue Biopharma, Inc. - 8-K, Current Report3
14.05.Cue Biopharma reports Q1 loss, secures $30M financing1
14.05.Cue Biopharma, Inc. - 10-Q, Quarterly Report2
14.05.Cue Biopharma, Inc.: Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments538Enhanced the company's portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program...
► Artikel lesen
11.05.Cue Biopharma appoints Shao-Lee Lin as CEO, President and Director1
08.05.Cue Biopharma, Inc.: Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)4
01.05.Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?37
30.04.Cue Biopharma appoints Shao-Lee Lin as CEO and president1
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1